P
Peter M.A. Calverley
Researcher at Boston University
Publications - 6
Citations - 505
Peter M.A. Calverley is an academic researcher from Boston University. The author has contributed to research in topics: COPD & Exacerbation. The author has an hindex of 5, co-authored 6 publications receiving 481 citations. Previous affiliations of Peter M.A. Calverley include University of Kiel.
Papers
More filters
Journal ArticleDOI
An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease
Bartolome R. Celli,Marc Decramer,Jadwiga A. Wedzicha,Kevin C. Wilson,Alvar Agustí,Gerard J. Criner,William MacNee,Barry Make,Stephen I. Rennard,Robert A. Stockley,Claus Vogelmeier,Antonio Anzueto,David H. Au,Peter J. Barnes,Pierre-Régis Burgel,Peter M.A. Calverley,Ciro Casanova,Enrico Clini,Christopher B. Cooper,Harvey O. Coxson,Daniel Dusser,Leonardo M. Fabbri,Bonnie Fahy,Gary T. Ferguson,Andrew M. Fisher,Monica Fletcher,Maurice Hayot,John R. Hurst,Paul Jones,Donald A. Mahler,François Maltais,David M. Mannino,Fernando J. Martinez,Marc Miravitlles,Paula Meek,Alberto Papi,Klaus F. Rabe,Nicolas Roche,Frank C. Sciurba,Sanjay Sethi,NM Siafakas,Don D. Sin,Joan B. Soriano,James K. Stoller,Donald P. Tashkin,Thierry Troosters,G.M. Verleden,Johny Verschakelen,Jørgen Vestbo,John W. Walsh,George R. Washko,Robert A. Wise,Emiel F.M. Wouters,Richard ZuWallack +53 more
TL;DR: This ATS/ERS Research Statement highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centered outcomes.
An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease Executive Summary
Bartolome R. Celli,Marc Decramer,Jadwiga A. Wedzicha,Kevin C. Wilson,Alvar Agust,Gerard J. Criner,William MacNee,Barry Make,Stephen I. Rennard,Robert A. Stockley,Claus Vogelmeier,Antonio Anzueto,David H. Au,Peter J. Barnes,Pierre-Régis Burgel,Peter M.A. Calverley,Ciro Casanova,Enrico Clini,Christopher B. Cooper,Harvey O. Coxson,Daniel Dusser,Leonardo M. Fabbri,Bonnie Fahy,Gary T. Ferguson,Andrew J. Fisher,Monica Fletcher,Maurice Hayot,John R. Hurst,Paul Jones,Donald A. Mahler,François Maltais,David M. Mannino,Fernando J. Martinez,Marc Miravitlles,Paula Meek,Alberto Papi,Klaus F. Rabe,Nicolas Roche,Frank C. Sciurba,Sanjay Sethi,Nikos M. Siafakas,Don D. Sin,Joan B. Soriano,James K. Stoller,Donald P. Tashkin,Thierry Troosters,G.M. Verleden,Johny Verschakelen,Jørgen Vestbo,John W. Walsh,George R. Washko,Robert A. Wise,Emiel F.M. Wouters,Richard ZuWallack +53 more
TL;DR: The ATS/ERS Research Statement as discussed by the authors highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centered outcomes, and provides recommendations for future research.
Journal ArticleDOI
Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype
Jadwiga A. Wedzicha,Klaus F. Rabe,Klaus F. Rabe,Fernando J. Martinez,Dirk Bredenbröker,Manja Brose,Udo-Michael Goehring,Peter M.A. Calverley +7 more
TL;DR: Treatment with roflumilast shifts patients from the frequent to the more stable infrequent exacerbator state, and the reduction in severe exacerbations leading to hospitalization/death was similar between subgroups and occurred independently of concomitant long-acting β2-agonists or previous inhaled corticosteroid treatment.
Iconographies supplémentaires de l'article : Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial
Fernando J. Martinez,Joseph Boscia,Gregory Feldman,Catherine Scott-Wilson,Sally Kilbride,Leonardo M. Fabbri,Courtney Crim,Peter M.A. Calverley +7 more
The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide
Jadwiga A. Wedzicha,Peter M.A. Calverley,Terence A. R. Seemungal,Gerry Hagan,Zainab Ansari,Robert Stockley +5 more
TL;DR: A small statistically significant beneficial effect was found on health status, with an unexpected finding of lower deaths in salmeterol/fluticasone propionate treated patients.